No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Chemicals - Specialty
Wacker Chemie AG is a global enterprise delivering a diverse portfolio of chemical products through its worldwide operations. The company's business is structured across four principal divisions: Wacker Silicones, Wacker Polymers, Wacker Biosolutions, and Wacker Polysilicon. The Wacker Silicones segment produces an extensive array of silicone-based items, including silanes, siloxanes, fluids, emulsions, elastomers, resins, and pyrogenic silicas, which are essential for industries such as construction, electronics, automotive, healthcare, and renewable energy. Meanwhile, Wacker Polymers specializes in the provision of binders and polymeric additives, notably dispersible polymer powders and vinyl acetate-ethylene dispersions, crucial for applications in construction, paper manufacturing, adhesives, paints, coatings, and fundamental chemical processes. Wacker Biosolutions focuses on bespoke biotechnological solutions and a specialized catalog of fine chemicals. Its offerings, encompassing pharmaceutical proteins, vaccines, cyclodextrins, cysteine, polyvinyl acetate solid resins, and acetylacetone, serve as key components for pharmaceutical active ingredients, food additives, and agricultural chemicals. Finally, the Wacker Polysilicon unit is dedicated to manufacturing hyperpure polysilicon, an indispensable material for both the semiconductor and solar energy sectors. Tracing its origins back to 1914, Wacker Chemie AG maintains its headquarters in Munich, Germany, and functions as a subsidiary of Dr. Alexander Wacker Familiengesellschaft mbH.
www.wacker.comNo one on the platform currently holds WCH.DE.
No tracked institution reports a position in WCH.DE as of their last filing.
No one on the platform has traded WCH.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -4.1% | 3.2% | ||||
| Profit Margin % | -15.0% | 4.5% | 2.7% | |||
| Free Cash Flow Margin % | -0.1% | 3.5% | 4.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $5.7B | +4.5% | $1.87 | $1.42–$2.56 | — | 4 |
| 2027 | $5.9B | +2.8% | $2.31 | $0.22–$3.31 | — | 5 |
| 2028 | $6.1B | +4.6% | $3.76 | $1.77–$4.78 | — | 6 |
| 2029 | $6.2B | +0.6% | $4.75 | $4.30–$5.09 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $0.36 | $6.99 | +1841.7% |
| 2026-04-29 | $0.11 | $0.21 | +83.6% |
| 2026-03-11 | $1.09 | $1.25 | +14.7% |
| 2025-10-29 | $1.20 | $-1.73 | -244.4% |
| 2025-07-31 | $0.01 | $-0.62 | -4631.2% |
| 2025-04-30 | $0.32 | $-0.16 | -150.6% |
| 2025-03-12 | $2.26 | $2.80 | +23.9% |
| 2024-10-28 | $0.59 |
| $0.56 |
| -5.1% |
| +1.65% |
| $5.5B |
| — |
| I93.FIndorama Ventures Public Company Limited | $0.73 | +3.52% | $4.5B | — |
| LXS.DELanxess AG | $13.64 | -2.57% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry